Kadimastem and iTolerance Submit Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT) Meeting Request with FDA for Potential Cure for Type 1 Diabetes
–News Direct– Kadimastem Ltd. (TASE:KDST), a clinical cell therapy company developing a cell therapy treatment for ALS and a potential…